Supernus Pharmaceuticals reported a 4% increase in total revenues to $149.8 million for the first quarter of 2025, driven by strong growth in Qelbree® and GOCOVRI® sales. Despite an increase in operating loss, adjusted operating earnings saw a significant rise. The company also successfully launched ONAPGO™.
Total revenues increased 4% to $149.8 million in Q1 2025 compared to the same period in 2024.
Qelbree® net sales surged by 44% to $64.7 million, and GOCOVRI® net sales increased by 16% to $30.7 million.
Operating loss was $(10.3) million, primarily due to higher contingent consideration loss and increased selling and marketing expenses.
Adjusted operating earnings grew by 16% to $25.9 million.
Supernus Pharmaceuticals reiterates its full-year 2025 financial guidance, projecting total revenues between $600 million and $630 million, and adjusted operating earnings between $105 million and $130 million.
Analyze how earnings announcements historically affect stock price performance